免疫組織化學市場－全球產業規模、佔有率、趨勢、機會與預測，按產品、應用、最終用戶、地區和競爭情況細分，2020-2030 年

2024 年全球免疫組織化學市場價值為 23.8 億美元，預計到 2030 年將達到 35.6 億美元，複合年成長率為 6.90%。全球免疫組織化學市場正在經歷大幅成長，其主要推動因素包括技術創新、對消費者驅動的醫療保健的需求不斷成長、慢性病發病率上升以及對預防保健的日益關注。免疫組織化學產品包括血液檢測和懷孕試劑盒、血糖監測儀和過敏測試解決方案，正逐漸成為個人管理自身健康的重要工具。這些設備使用戶能夠獨立監測各種健康參數，從而無需臨床就診，並使消費者能夠控制自己的健康。

市場的成長軌跡依然強勁，這得益於診斷技術的進步、消費者健康意識的增強以及向更實惠、更便捷和個性化的健康解決方案的轉變。隨著這些免疫組織化學產品在健康管理策略中變得越來越重要，市場預計將繼續擴大。監管支持和診斷領域的持續創新進一步增強了市場的潛力，使免疫組織化學領域成為醫療保健和診斷行業利益相關者的有利可圖的機會。

關鍵市場促進因素

慢性病和傳染病發生率上升

主要市場挑戰

儀器和試劑成本高

主要市場趨勢

數位病理學和人工智慧 (AI) 與 IHC 的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球免疫組織化學市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（抗體、設備、試劑、試劑盒）
  • 依應用（診斷、癌症、傳染病、心血管疾病、自體免疫疾病、糖尿病、腎臟疾病、研究）
  • 按最終用戶（醫院和診斷實驗室、研究機構、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美免疫組織化學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲免疫組織化學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太免疫組織化學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲免疫組織化學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲免疫組織化學市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球免疫組織化學市場：SWOT 分析

第 14 章：競爭格局

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer US LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

第 15 章：策略建議

第16章調查會社について,免責事項

Global Immunohistochemistry market was valued at USD 2.38 Billion in 2024 and is expected to reach USD 3.56 Billion by 2030 with a CAGR of 6.90%. The global Immunohistochemistry market is undergoing substantial growth, fueled by key drivers such as technological innovation, increasing demand for consumer-driven healthcare, the rising incidence of chronic diseases, and a growing focus on preventive care. Immunohistochemistry products ranging from blood tests and pregnancy kits to glucose monitors and allergy testing solutions are progressively becoming integral tools for individuals managing their own health. These devices enable users to monitor a variety of health parameters independently, eliminating the need for clinical visits and empowering consumers to take control of their health.

The market's growth trajectory remains robust, underpinned by advancements in diagnostic technologies, heightened consumer health consciousness, and a shift toward more affordable, accessible, and personalized health solutions. As these Immunohistochemistry products become increasingly central to health management strategies, the market is expected to continue expanding. Regulatory support and ongoing innovations in diagnostics further enhance the market's potential, positioning the Immunohistochemistry segment as a lucrative opportunity for stakeholders in the healthcare and diagnostics industries.

Key Market Drivers

Rising Incidence of Chronic and Infectious Diseases

The global surge in chronic and infectious diseases has become one of the most significant demand drivers for the Immunohistochemistry (IHC) market. This trend is not only reshaping diagnostic approaches but also creating sustained growth opportunities for IHC-related products and services across healthcare systems worldwide. Chronic diseases represent the primary driver of global mortality and long-term disability, exerting substantial pressure on healthcare systems and economies. In 2020, these conditions such as cancer, cardiovascular disease, and diabetes were responsible for or contributed to 79% of all deaths worldwide. This figure is expected to rise to 84% by 2030, underscoring the urgent need for advanced diagnostic and therapeutic solutions, particularly in high-burden regions and aging populations. As the prevalence of chronic diseases particularly cancer, cardiovascular disorders, diabetes, and autoimmune conditions continues to rise globally, the need for precise, tissue-based diagnostic techniques has become critical. Immunohistochemistry, which allows for the detection of specific antigens in cells of a tissue section using labeled antibodies, is widely regarded as a gold-standard diagnostic tool, particularly in oncology. The technique aids in tumor classification, grading, and staging, directly influencing treatment decisions. In oncology, IHC is essential in detecting biomarkers such as HER2, Ki-67, and PD-L1, which guide targeted therapy. In autoimmune diseases, IHC helps identify inflammatory markers and immune cell infiltration patterns.

Malaria continues to pose a critical public health challenge, with approximately 249 million cases and over 608,000 deaths reported annually, disproportionately affecting children under the age of five in sub-Saharan Africa. Dengue presents an equally pressing concern, placing over 3.9 billion people globally at risk. The disease leads to millions of infections and thousands of fatalities each year, particularly in densely populated urban regions across Asia and Latin America. With the re-emergence and evolution of infectious diseases (e.g., tuberculosis, HIV, hepatitis, and most recently, COVID-19), there is growing interest in applying IHC techniques to pathogen detection and tissue-based immune response analysis. IHC is particularly useful in understanding the histopathological impact of viruses and bacteria on human tissues, which plays a crucial role in research and case-specific diagnosis, especially in post-mortem and advanced-stage analyses. This has been further amplified by the COVID-19 pandemic, which increased awareness of tissue-based diagnostic tools to study viral impact at the cellular level, thereby expanding the IHC use case beyond traditional cancer diagnostics. The World Health Organization (WHO) projects that non-communicable diseases (NCDs) will account for nearly 75% of all deaths by 2030. This projection is influencing both public and private healthcare institutions to adopt early and accurate diagnostic frameworks, where IHC plays a vital role. Simultaneously, growing healthcare spending especially in emerging economies is increasing access to sophisticated diagnostic platforms.

Key Market Challenges

High Cost of Instruments and Reagents

Despite the growing demand for immunohistochemistry in clinical diagnostics and pharmaceutical research, the high capital and operational costs associated with IHC instruments and reagents remain a significant barrier to market expansion, particularly in low- and middle-income countries (LMICs). Advanced IHC systems-including automated slide stainers, image analyzers, and digital pathology platforms require substantial upfront investment.

Recurrent costs of high-quality primary and secondary antibodies, detection kits, and substrate reagents are also high, especially for multiplexed or customized panels. Smaller pathology labs and diagnostic centers in emerging markets often lack the budget or funding mechanisms to acquire and maintain these systems, limiting the adoption of IHC technology. This cost barrier not only restricts market penetration in cost-sensitive regions but also slows down lab modernization in under-resourced healthcare systems.

Key Market Trends

Integration of Digital Pathology and Artificial Intelligence (AI) with IHC

The convergence of immunohistochemistry with digital pathology and AI-driven image analysis is redefining how tissue diagnostics are performed and interpreted. This trend is not only enhancing diagnostic accuracy but also improving scalability, standardization, and workflow efficiency. Digital slide scanners now allow high-resolution imaging of IHC-stained tissue, enabling remote diagnosis, archiving, and secondary consultations. AI algorithms are being developed to automatically quantify biomarker expression, such as HER2 or PD-L1, minimizing subjectivity and variability in interpretation.

AI-assisted platforms are accelerating the turnaround time for high-volume labs and facilitating telepathology, especially in resource-constrained or rural areas. This trend is transforming IHC from a manual, pathologist-driven technique to a more automated, data-driven process, making it attractive to both clinical and research sectors and opening up opportunities for scalable global adoption.

Key Market Players

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer U.S. LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

Report Scope:

In this report, the Global Immunohistochemistry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunohistochemistry Market, By Product:

• Antibodies
• Equipment
• Reagents
• Kits

Immunohistochemistry Market, By Application:

• Diagnostics
• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Research

Immunohistochemistry Market, By End User:

• Hospitals & Diagnostic Laboratories
• Research Institutes
• Others

Immunohistochemistry Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunohistochemistry Market.

Available Customizations:

Global Immunohistochemistry market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunohistochemistry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Antibodies, Equipment, Reagents, Kits)
  • 5.2.2. By Application (Diagnostics, Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Nephrological Diseases, Research)
  • 5.2.3. By End User (Hospitals & Diagnostic Laboratories, Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Immunohistochemistry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunohistochemistry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Immunohistochemistry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Immunohistochemistry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Immunohistochemistry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunohistochemistry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Immunohistochemistry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Immunohistochemistry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Immunohistochemistry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Immunohistochemistry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Immunohistochemistry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Immunohistochemistry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Immunohistochemistry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Immunohistochemistry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Immunohistochemistry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Immunohistochemistry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Immunohistochemistry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Immunohistochemistry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Immunohistochemistry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Immunohistochemistry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Immunohistochemistry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Immunohistochemistry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Immunohistochemistry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Immunohistochemistry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Immunohistochemistry Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Merck KGaA
• 14.4. Danaher Corporation
• 14.5. PerkinElmer U.S. LLC
• 14.6. Bio-Rad Laboratories, Inc.
• 14.7. Cell Signaling Technology, Inc.
• 14.8. Bio SB
• 14.9. Agilent Technologies, Inc.
• 14.10.Abcam Limited

15. Strategic Recommendations

16. About Us & Disclaimer